AZD9150, a STAT3 ASO, is undergoing phase 1 clinical trials for patients with advanced hepatocellular carcinoma (HCC) [NCT01839604] as well as advanced solid malignancies [NCT03394144]. The gene discussed is STAT3; the disease is hepatocellular carcinoma.